Celldex Therapeutics
CLDX
131 hedge funds and large institutions have $172M invested in Celldex Therapeutics in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 17 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
16% more call options, than puts
Call options by funds: $1.16M | Put options by funds: $998K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.34% less ownership
Funds ownership: 3.84% → 3.5% (-0.34%)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
3% less funds holding
Funds holding: 135 → 131 (-4)
23% less capital invested
Capital invested by funds: $223M → $172M (-$50.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$18.6M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.61M |
| 3 |
JP Morgan Chase
New York
|
+$2.49M |
| 4 |
TA
Teachers Advisors
New York
|
+$1.65M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.54M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.27M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$2.48M |
| 4 |
AG
Artal Group
Luxembourg
|
-$995K |
| 5 |
Millennium Management
New York
|
-$870K |
CLDX Hedge Fund Activity: Q1 2018 in Review
131 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2018, worth a combined $172M — down 23% from $223M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CLDX and 16 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 39 added.
The largest buyer was Ameriprise, adding an estimated $18.6M. The largest seller was Vanguard Group, cutting an estimated $6.54M.
- 131 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2018, down from 135 in Q4 2017.
- Funds reported $172M of Celldex Therapeutics stock for Q1 2018, down 23% quarter-over-quarter.
- 16 funds opened new Celldex Therapeutics positions in Q1 2018 and 17 closed out, a net change of -1 holder.
- The largest Celldex Therapeutics buyer in Q1 2018 was Ameriprise, an estimated $18.6M added.
- The largest Celldex Therapeutics seller in Q1 2018 was Vanguard Group, an estimated $6.54M sold.
Based on aggregated 13F filings for Q1 2018.